# US 2016/0238619 A1 · Methods for measuring concentrations of biomolecules

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0238619 A1
- Document ID: US20160238619A1
- Status: Published application
- Kind: A1
- Application number: 15/146,780
- Filed: 2016-05-04
- Published: 2016-08-18
- Earliest claimed: 2011-12-02
- Assignees: C2N Diagnostics
- Applicants: C2N Diagnostics
- Inventors: Tim West; Andrew Corey Paoletti
- Web page: https://patentgrep.com/patent/US20160238619A1

## CPC

- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G16B 25/00: ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G01N 2333/47: Assays involving proteins of known structure or function as defined in the subgroups
- G01N 2458/15: Non-radioactive isotope labels, e.g. for detection by mass spectrometry
- G01N 2560/00: Chemical aspects of mass spectrometric analysis of biological material
- G01N 2800/28: Neurological disorders
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

The present invention provides methods for measuring the absolute concentration of a biomolecule of interest in a subject. Such biomolecules may be implicated in one or more neurological and neurodegenerative diseases or disorders. Also provided is a method for determining whether a therapeutic agent affects the in vivo metabolism of a central nervous system derived biomolecule. Also provided are kits for performing the methods of the invention.

## Claims

### Claim 1

A method of calculating the concentration of a biomolecule in a subject comprising:
(a) contacting a sample from the subject with a Quantitation Standard, wherein the Quantitation Standard comprises a known concentration of a labeled biomolecule of interest;
(b) isolating the biomolecule of interest from the sample, wherein (a) and (b) can occur in reverse order;
(c) determining a ratio of labeled to unlabeled biomolecules in the sample; and
(d) calculating the concentration of the unlabeled biomolecule in the sample.

### Claim 2 (depends on 1)

The method of claim 1, wherein calculating the concentration of the unlabeled biomolecule comprises multiplying the known concentration of the Quantitation Standard with the ratio of labeled to unlabeled biomolecules in the sample.

### Claim 3 (depends on 1)

The method of claim 1, further comprising normalizing the calculated concentration to a standard curve, wherein the standard curve is generated by determining two or more ratios of unlabeled to Quantitation Standard, wherein the concentration of the unlabeled biomolecule is known.

### Claim 4 (depends on 1)

The method of claim 1, wherein the Quantitation Standard comprises one or more labeled moieties.

### Claim 5 (depends on 4)

The method of claim 4, wherein the one or more labeled moieties comprise a non-radioactive isotope that is selected from the group consisting of 2H, 13C, 15N, 17O, 18O, 33S, 34S, and 36S.

### Claim 6 (depends on 1)

The method of claim 1, wherein the biomolecule is selected from the group consisting of peptides, lipids, nucleic acids, and carbohydrates.

### Claim 7 (depends on 6)

The method of claim 6, wherein the biomolecule is a protein that is synthesized in the central nervous system (CNS).

### Claim 8 (depends on 4)

The method of claim 4, wherein the labeled moiety is a labeled amino acid.

### Claim 9 (depends on 1)

The method of claim 1, further comprising comparing the concentration of the unlabeled biomolecule of interest to the concentration of the same biomolecule in a corresponding normal sample, to the concentration of the same biomolecule in a subject of known neurological or neurodegenerative disease state, to the concentration of the same biomolecule from the same subject determined at an earlier time, or any combination thereof.

### Claim 10 (depends on 1)

The method of claim 1, wherein the neurological or neurodegenerative disease is selected from the group consisting of Alzheimer's Disease, Parkinson's Disease, stroke, frontal temporal dementias (FTDs), Huntington's Disease, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), aging-related disorders and dementias, Multiple Sclerosis, Prion Diseases, Lewy Body Disease, Pick's Disease, motor neuron diseases, restless leg syndrome, seizure disorders, tremors, depression, mania, anxiety disorders, brain trauma or injury, narcolepsy, sleep disorders, autism, normal pressure hydrocephalus, pain disorders or syndromes, migraines, headaches, spinocerebellar disorders, muscular dystrophies, myasthenia gravis, retinal degeneration and Amyotrophic Lateral Sclerosis.

### Claim 11

An in vivo method of quantifying the concentration of one or more biomolecules in a subject comprising:
(a) administering one or more labeled amino acids to the subject, wherein the labeled amino acids incorporate into a biomolecule of interest in the subject;
(b) obtaining a sample of biological fluid or tissue from the subject, wherein the sample comprises a labeled biomolecule fraction and an unlabeled biomolecule fraction;
(c) contacting the sample with a Quantitation Standard, wherein the Quantitation Standard comprises a known concentration of a biomolecule labeled with a moiety that has a molecular weight that differs from the one or more labeled amino acids administered to the subject;
(d) determining a ratio of labeled to unlabeled biomolecules in the sample, a ratio of labeled biomolecule to the Quantitation Standard, and a ratio of unlabeled biomolecule to the Quantitation Standard; and
(e) calculating the concentration of the unlabeled biomolecule and the concentration of the labeled biomolecule in the sample.

### Claim 12 (depends on 11)

The method of claim 11, wherein calculating the concentration of the unlabeled biomolecule comprises multiplying the concentration of the Quantitation Standard with the determined ratio of unlabeled biomolecule to the Quantitation Standard.

### Claim 13 (depends on 11)

The method of claim 11, wherein calculating the concentration of the labeled biomolecule comprises multiplying the concentration of the Quantitation Standard with the determined ratio of labeled biomolecule to the Quantitation Standard.

### Claim 14 (depends on 11)

The method of claim 11, further comprising normalizing the calculated concentration of unlabeled biomolecule to an unlabeled standard curve, and normalizing the calculated concentration of labeled biomolecule to a labeled standard curve, wherein each of the standard curves is generated by determining two or more ratios of unlabeled or labeled biomolecules to Quantitation Standard, wherein the concentration of unlabeled or labeled biomolecule is known.

### Claim 15 (depends on 11)

The method of claim 11, wherein the labeled amino acid and the Quantitation Standard are independently labeled with a non-radioactive isotope selected from the group consisting of 2H, 13C, 15N, 17O, 18O, 33S, 34S, and 36S.

### Claim 16 (depends on 15)

The method of claim 15, wherein the labeled amino acid is an essential or nonessential amino acid.

### Claim 17 (depends on 11)

The method of claim 11, wherein the biomolecule is selected from the group consisting of a peptide, a lipid, a nucleic acid, and a carbohydrate.

### Claim 18 (depends on 17)

The method of claim 17, wherein the biomolecule is a peptide that is synthesized in the central nervous system (CNS).

### Claim 19 (depends on 11)

The method of claim 11, wherein known concentrations of one or more labeled amino acids are administered to the subject and the concentrations of two or more biomolecules are calculated.

### Claim 20 (depends on 11)

The method of claim 11, wherein the sample is selected from the group consisting of cerebral spinal fluid (CSF), blood, plasma, urine, saliva, and tears.

### Claim 21 (depends on 11)

The method of claim 11, further comprising comparing the concentration of the unlabeled biomolecule of interest to the concentration of the same biomolecule in a corresponding normal sample, to the concentration of the same biomolecule in a subject of known neurological or neurodegenerative disease state, to the concentration of the same biomolecule from the same subject determined at an earlier time, or any combination thereof.

### Claim 22 (depends on 21)

The method of claim 21, wherein the neurological or neurodegenerative disease is selected from the group consisting of Alzheimer's Disease, Parkinson's Disease, stroke, frontal temporal dementias (FTDs), Huntington's Disease, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), aging-related disorders and dementias, Multiple Sclerosis, Prion Diseases, Lewy Body Disease, Pick's Disease, motor neuron diseases, restless leg syndrome, seizure disorders, tremors, depression, mania, anxiety disorders, brain trauma or injury, narcolepsy, sleep disorders, autism, normal pressure hydrocephalus, pain disorders or syndromes, migraines, headaches, spinocerebellar disorders, muscular dystrophies, myasthenia gravis, retinal degeneration and Amyotrophic Lateral Sclerosis.

### Claim 23

A kit for diagnosing or monitoring the progression or treatment of a neurological or neurodegenerative disease in a subject, the kit comprising:
(a) one or more labeled amino acids;
(b) means for administering the one or more labeled amino acids to the subject, whereby the labeled amino acids are capable of incorporating into and labeling a biomolecule of interest in the subject;
(c) means for obtaining a biological sample at regular time intervals from the subject, wherein the sample comprises a labeled biomolecule fraction and an unlabeled biomolecule fraction;
(d) instructions for detecting and determining the ratio of labeled to unlabeled biomolecules of interest over time and for calculating the concentration of the unlabeled biomolecule in the sample, whereby the concentration of unlabeled biomolecule may be compared to the concentration of the same biomolecule in a corresponding normal sample, to the concentration of the same biomolecule in a subject of known neurological or neurodegenerative disease state, to the concentration of the same biomolecule from the same subject determined at an earlier time, or any combination thereof.

### Claim 24 (depends on 23)

The kit of claim 23, wherein the labeled amino acid is an essential or nonessential amino acid.

### Claim 25 (depends on 23)

The kit of claim 23, wherein the labeled amino acid comprises a non-radioactive atom.

### Claim 26 (depends on 25)

The kit of claim 25, wherein the non-radioactive atom is selected from the group consisting of 2H, 13C, 15N, 17O, 18O, 33S, 34S, and 36S.

### Claim 27 (depends on 23)

The kit of claim 23, wherein the biomolecule is selected from the group consisting of a peptide, a lipid, a nucleic acid, and a carbohydrate.

### Claim 28 (depends on 27)

The kit of claim 27, wherein the biomolecule is a peptide that is synthesized in the central nervous system (CNS).

### Claim 29 (depends on 23)

The kit of claim 23, wherein the neurological or neurodegenerative disease is selected from the group consisting of Alzheimer's Disease, Parkinson's Disease, stroke, frontal temporal dementias (FTDs), Huntington's Disease, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), aging-related disorders and dementias, Multiple Sclerosis, Prion Diseases, Lewy Body Disease, Pick's Disease, motor neuron diseases, restless leg syndrome, seizure disorders, tremors, depression, mania, anxiety disorders, brain trauma or injury, narcolepsy, sleep disorders, autism, normal pressure hydrocephalus, pain disorders or syndromes, migraines, headaches, spinocerebellar disorders, muscular dystrophies, myasthenia gravis, retinal degeneration and Amyotrophic Lateral Sclerosis.
